Magnetic resonance guided high-intensity focused ultrasound for image-guided temperature-induced drug delivery

Advanced Drug Delivery Reviews

Volumn 72, Issue , 2014, Pages 65-81

  Hijnen, Nicole ^a,c   Langereis, Sander ^b,c   Grüll, Holger ^a,b,c  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c Center for Imaging Research and Education (CIRE)   (Netherlands)

Author keywords

Doxorubicin; Drug delivery; MR image guidance; MR HIFU; Temperature sensitive liposomes; Ultrasound

Indexed keywords

DRUG DELIVERY; LIPOSOMES; MAGNETIC RESONANCE IMAGING; ONCOLOGY; ULTRASONICS;

DOXORUBICIN; HIGH INTENSITY FOCUSED ULTRASOUND; LIPOSOMAL FORMULATION; MR IMAGES; MR-HIFU; NON-INVASIVE TECHNOLOGY; TEMPERATURE-SENSITIVE; TEMPERATURE-SENSITIVE LIPOSOMES;

MAGNETIC RESONANCE;

ANIMAL; DRUG DELIVERY SYSTEM; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TEMPERATURE;

ANIMALS; DRUG DELIVERY SYSTEMS; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; TEMPERATURE;

EID: 84901607601     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.01.006     Document Type: Review

References (157)

1. Sawyers C.L. Perspective: combined forces. Nature 2013, 498:S7.
2. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
3. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
4. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24:1211-1217.
5. Sanhai W.R., Sakamoto J.H., Canady R., Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3:242-244.
6. Parveen S., Misra R., Sahoo S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8:147-166.
7. Working P.K., Newman M.S., Huang S.K., Mayhew E., Vaage J., Lasic D.D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). J. Liposome Res. 1994, 4:667-687.
8. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol. 2005, 391:71-97.
9. Chang H.I., Yeh M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 2012, 7:49-60.
10. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
11. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 1993, 53:3765-3770.
12. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 2010, 21:797-802.
13. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 2012, 164:138-144.
14. Nagy J.A., Benjamin L., Zeng H., Dvorak A.M., Dvorak H.F. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
15. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
16. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
17. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148:135-146.
18. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65:71-79.
19. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-)clinical progress. J. Control. Release 2012, 161:175-187.
20. Yatvin M.B., Weinstein J.N., Dennis W.H., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202:1290-1293.
21. Weinstein J.N., Magin R.L., Yatvin M.B., Zaharko D.S. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 1979, 204:188-191.
22. Landon C., Park J.Y., Needham D., Dewhirst M.W. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature sensitive liposomes used in combination with mild hypertheria in the treatment of local cancer. Open Nanomedicine J. 2011, 3:38-64.
23. ClinicalTrials.gov Phase 1/2 Study of ThermoDox™ With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall 2009.
24. ClinicalTrials.gov A Study of ThermoDox™ in Combination with Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver 2007.
25. ClinicalTrials.gov Phase 3 Study of ThermoDox™ with Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) 2008.
26. Poon R.T., Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert. Opin. Pharmacother. 2009, 10:333-343.
27. Wood B.J., Poon R.T., Locklin J.K., Dreher M.R., Ng K.K., Eugeni M., Seidel G., Dromi S., Neeman Z., Kolf M., Black C.D., Prabhakar R., Libutti S.K. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J. Vasc. Interv. Radiol. 2012, 23:248-255. (e247).
28. Habash R.W., Bansal R., Krewski D., Alhafid H.T. Thermal therapy, part 2: hyperthermia techniques. Crit. Rev. Biomed. Eng. 2006, 34:491-542.
29. Helmberger T., Marti-Bonmati L., Pereira P., Gillams A., Martinez J., Lammer J., Malagari K., Gangi A., de Baere T., Adam E.J., Rasch C., Budach V., Reekers J.A. Radiologists' leading position in image-guided therapy. Insights Imag. 2013, 4:1-7.
30. Cline H.E., Hynynen K., Hardy C.J., Watkins R.D., Schenck J.F., Jolesz F.A. MR temperature mapping of focused ultrasound surgery. Magn. Reson. Med. 1994, 31:628-636.
31. McDannold N.J., King R.L., Jolesz F.A., Hynynen K.H. Usefulness of MR imaging-derived thermometry and dosimetry in determining the threshold for tissue damage induced by thermal surgery in rabbits. Radiology 2000, 216:517-523.
32. Gellermann J., Hildebrandt B., Issels R., Ganter H., Wlodarczyk W., Budach V., Felix R., Tunn P.U., Reichardt P., Wust P. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer 2006, 107:1373-1382.
33. Stakhursky V.L., Arabe O., Cheng K.S., Macfall J., Maccarini P., Craciunescu O., Dewhirst M., Stauffer P., Das S.K. Real-time MRI-guided hyperthermia treatment using a fast adaptive algorithm. Phys. Med. Biol. 2009, 54:2131-2145.
34. Ludemann L., Wlodarczyk W., Nadobny J., Weihrauch M., Gellermann J., Wust P. Non-invasive magnetic resonance thermography during regional hyperthermia. Int. J. Hyperthermia 2010, 26:273-282.
35. Hynynen K. MRI-guided focused ultrasound treatments. Ultrasonics 2010, 50:221-229.
36. Stewart E.A. Uterine fibroids. Lancet 2001, 357:293-298.
37. Hindley J., Gedroyc W.M., Regan L., Stewart E., Tempany C., Hynyen K., McDannold N., Inbar Y., Itzchak Y., Rabinovici J., Kim H.S., Geschwind J.F., Hesley G., Gostout B., Ehrenstein T., Hengst S., Sklair-Levy M., Shushan A., Jolesz F. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am. J. Roentgenol. 2004, 183:1713-1719.
38. Kim Y.S., Lim H.K., Kim J.H., Rhim H., Park B.K., Keserci B., Kohler M.O., Bae D.S., Kim B.G., Lee J.W., Kim T.J., Sokka S., Lee J.H. Dynamic contrast-enhanced magnetic resonance imaging predicts immediate therapeutic response of magnetic resonance-guided high-intensity focused ultrasound ablation of symptomatic uterine fibroids. Invest. Radiol. 2011, 46:639-647.
39. Voogt M.J., Trillaud H., Kim Y.S., Mali W.P., Barkhausen J., Bartels L.W., Deckers R., Frulio N., Rhim H., Lim H.K., Eckey T., Nieminen H.J., Mougenot C., Keserci B., Soini J., Vaara T., Kohler M.O., Sokka S., van den Bosch M.A. Volumetric feedback ablation of uterine fibroids using magnetic resonance-guided high intensity focused ultrasound therapy. Eur. Radiol. 2012, 22:411-417.
40. Napoli A., Anzidei M., Marincola B.C., Brachetti G., Ciolina F., Cartocci G., Marsecano C., Zaccagna F., Marchetti L., Cortesi E., Catalano C. Primary pain palliation and local tumor control in bone metastases treated with magnetic resonance-guided focused ultrasound. Invest. Radiol. 2013, 48:351-358.
41. Lipsman N., Schwartz M.L., Huang Y., Lee L., Sankar T., Chapman M., Hynynen K., Lozano A.M. MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. Lancet Neurol. 2013, 12:462-468.
42. Huber P.E., Jenne J.W., Rastert R., Simiantonakis I., Sinn H.P., Strittmatter H.J., von Fournier D., Wannenmacher M.F., Debus J. A new noninvasive approach in breast cancer therapy using magnetic resonance imaging-guided focused ultrasound surgery. Cancer Res. 2001, 61:8441-8447.
43. Chopra R., Colquhoun A., Burtnyk M., N'Djin A., Kobelevskiy W.I., Boyes A., Siddiqui K., Foster H., Sugar L., Haider M.A., Bronskill M., Klotz L. MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology 2012, 265:303-313.
44. Hahn G.M. Hyperthermia and Cancer 1982, Plenum Press, New York.
45. Horsman M.R., Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 2007, 19:418-426.
46. Roti Roti J.L. Introduction: radiosensitization by hyperthermia. Int. J. Hyperthermia 2004, 20:109-114.
47. Dewhirst M.W., Vujaskovic Z., Jones E., Thrall D. Re-setting the biologic rationale for thermal therapy. Int. J. Hyperthermia 2005, 21:779-790.
48. Issels R.D. Hyperthermia adds to chemotherapy. Eur. J. Cancer 2008, 44:2546-2554.
49. Roti Roti J.L. Cellular responses to hyperthermia (40-46°C): cell killing and molecular events. Int. J. Hyperthermia 2008, 24:3-15.
50. Baronzio G., Freitas I., Griffini P., Bertone V., Pacini F., Mascaro G., Razzini E., Gramaglia A. Omega-3 fatty acids can improve radioresponse modifying tumor interstitial pressure, blood rheology and membrane peroxidability. Anticancer Res. 1994, 14:1145-1154.
51. Kong G., Braun R.D., Dewhirst M.W. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001, 61:3027-3032.
52. Overgaard J., Gonzalez Gonzalez D., Hulshof M.C., Arcangeli G., Dahl O., Mella O., Bentzen S.M. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int. J. Hyperthermia 1996, 12:3-20.
53. de Wit R., van der Zee J., van der Burg M.E., Kruit W.H., Logmans A., van Rhoon G.C., Verweij J. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. Br. J. Cancer 1999, 80:1387-1391.
54. van der Zee J., van Rhoon G.C. Cervical cancer: radiotherapy and hyperthermia. Int. J. Hyperthermia 2006, 22:229-234.
55. Franckena M., Fatehi D., de Bruijne M., Canters R.A., van Norden Y., Mens J.W., van Rhoon G.C., van der Zee J. Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia. Eur. J. Cancer 2009, 45:1969-1978.
56. Issels R.D., Lindner L.H., Verweij J., Wust P., Reichardt P., Schem B.C., Abdel-Rahman S., Daugaard S., Salat C., Wendtner C.M., Vujaskovic Z., Wessalowski R., Jauch K.W., Durr H.R., Ploner F., Baur-Melnyk A., Mansmann U., Hiddemann W., Blay J.Y., Hohenberger P. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010, 11:561-570.
57. Oleson J.R., Samulski T.V., Leopold K.A., Clegg S.T., Dewhirst M.W., Dodge R.K., George S.L. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment. Int. J. Radiat. Oncol. Biol. Phys. 1993, 25:289-297.
58. Kapp D.S., Cox R.S. Thermal treatment parameters are most predictive of outcome in patients with single tumor nodules per treatment field in recurrent adenocarcinoma of the breast. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33:887-899.
59. Sherar M., Liu F.F., Pintilie M., Levin W., Hunt J., Hill R., Hand J., Vernon C., van Rhoon G., van der Zee J., Gonzalez D.G., van Dijk J., Whaley J., Machin D. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 1997, 39:371-380.
60. Thrall D.E., LaRue S.M., Yu D., Samulski T., Sanders L., Case B., Rosner G., Azuma C., Poulson J., Pruitt A.F., Stanley W., Hauck M.L., Williams L., Hess P., Dewhirst M.W. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin. Cancer Res. 2005, 11:5206-5214.
61. Jones E., Thrall D., Dewhirst M.W., Vujaskovic Z. Prospective thermal dosimetry: the key to hyperthermia's future. Int. J. Hyperthermia 2006, 22:247-253.
62. Song C.W. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res. 1984, 44:4721s-4730s.
63. Vaupel P.W., Kelleher D.K. Pathophysiological and vascular characteristics of tumours and their importance for hyperthermia: heterogeneity is the key issue. Int. J. Hyperthermia 2010, 26:211-223.
64. Lynn J.G., Zwemer R.L., Chick A.J. The biological application of focused ultrasonic waves. Science 1942, 96:119-120.
65. Cline H.E., Schenck J.F., Watkins R.D., Hynynen K., Jolesz F.A. Magnetic resonance-guided thermal surgery. Magn. Reson. Med. 1993, 30:98-106.
66. Hynynen K., Freund W.R., Cline H.E., Chung A.H., Watkins R.D., Vetro J.P., Jolesz F.A. A clinical, noninvasive, MR imaging-monitored ultrasound surgery method. Radiographics 1996, 16:185-195.
67. Hynynen K. MRIgHIFU: a tool for image-guided therapeutics. J. Magn. Reson. Imaging 2011, 34:482-493.
68. Dewey W.C. Arrhenius relationships from the molecule and cell to the clinic. Int. J. Hyperthermia 2009, 25:3-20.
69. ter Haar G., Sinnett D., Rivens I. High intensity focused ultrasound-a surgical technique for the treatment of discrete liver tumours. Phys. Med. Biol. 1989, 34:1743-1750.
70. Hynynen K. The threshold for thermally significant cavitation in dog's thigh muscle in vivo. Ultrasound Med. Biol. 1991, 17:157-169.
71. Haar G.T., Coussios C. High intensity focused ultrasound: past, present and future. Int. J. Hyperthermia 2007, 23:85-87.
72. Ishihara Y., Calderon A., Watanabe H., Okamoto K., Suzuki Y., Kuroda K., Suzuki Y. A precise and fast temperature mapping using water proton chemical shift. Magn. Reson. Med. 1995, 34:814-823.
73. McDannold, Hynynen K., Wolf D., Wolf G., Jolesz F. MRI evaluation of thermal ablation of tumors with focused ultrasound. J. Magn. Reson. Imaging 1998, 8:91-100.
74. Rieke V., Butts Pauly K. MR thermometry. J. Magn. Reson. Imaging 2008, 27:376-390.
75. Denis de Senneville B., Quesson B., Moonen C.T. Magnetic resonance temperature imaging. Int. J. Hyperthermia 2005, 21:515-531.
76. Kickhefel A., Roland J., Weiss C., Schick F. Accuracy of real-time MR temperature mapping in the brain: a comparison of fast sequences. Phys. Med. 2010, 26:192-201.
77. Schlesinger D., Benedict S., Diederich C., Gedroyc W., Klibanov A., Larner J. MR-guided focused ultrasound surgery, present and future. Med. Phys. 2013, 40:080901.
78. Daum D.R., Hynynen K. A 256-element ultrasonic phased array system for the treatment of large volumes of deep seated tissue. IEEE Trans. Ultrason. Ferroelectr. Freq. Control 1999, 46:1254-1268.
79. Haar G.T., Coussios C. High intensity focused ultrasound: physical principles and devices. Int. J. Hyperthermia 2007, 23:89-104.
80. Fan X., Hynynen K. Ultrasound surgery using multiple sonications-treatment time considerations. Ultrasound Med. Biol. 1996, 22:471-482.
81. Köhler M.O., Mougenot C., Quesson B., Enholm J., Le Bail B., Laurent C., Moonen C.T., Ehnholm G.J. Volumetric HIFU ablation under 3D guidance of rapid MRI thermometry. Med. Phys. 2009, 36:3521-3535.
82. Ebbini E.S., Umemura S.I., Ibbini M., Cain C.A. A cylindrical-section ultrasound phased-array applicator for hyperthermia cancer therapy. IEEE Trans. Ultrason. Ferroelectr. Freq. Control 1988, 35:561-572.
83. Hijnen N.M., Heijman E., Kohler M.O., Ylihautala M., Ehnholm G.J., Simonetti A.W., Grull H. Tumour hyperthermia and ablation in rats using a clinical MR-HIFU system equipped with a dedicated small animal set-up. Int. J. Hyperthermia 2012, 28:141-155.
84. Enholm J.K., Köhler M.O., Quesson B., Mougenot C., Moonen C.T., Sokka S.D. Improved volumetric MR-HIFU ablation by robust binary feedback control. IEEE Trans. Biomed. Eng. 2010, 57:103-113.
85. de Smet M., Heijman E., Langereis S., Hijnen N.M., Grull H. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study. J. Control. Release 2011, 150:102-110.
86. Ranjan A., Jacobs G.C., Woods D.L., Negussie A.H., Partanen A., Yarmolenko P.S., Gacchina C.E., Sharma K.V., Frenkel V., Wood B.J., Dreher M.R. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J. Control. Release 2011, 158(3):487-494.
87. Partanen A., Yarmolenko P.S., Viitala A., Appanaboyina S., Haemmerich D., Ranjan A., Jacobs G., Woods D., Enholm J., Wood B.J., Dreher M.R. Mild hyperthermia with magnetic resonance-guided high-intensity focused ultrasound for applications in drug delivery. Int. J. Hyperthermia 2012, 28:320-336.
88. Ranjan A., Jacobs G.C., Woods D.L., Negussie A.H., Partanen A., Yarmolenko P.S., Gacchina C.E., Sharma K.V., Frenkel V., Wood B.J., Dreher M.R. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J. Control. Release 2012, 158:487-494.
89. Partanen A., Tillander M., Yarmolenko P.S., Wood B.J., Dreher M.R., Kohler M.O. Reduction of peak acoustic pressure and shaping of heated region by use of multifoci sonications in MR-guided high-intensity focused ultrasound mediated mild hyperthermia. Med. Phys. 2013, 40:013301.
90. Marsh D. Handbook of Lipid Bilayers 1990, CRC Press.
91. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., Colvin O.M., Needham D., Dewhirst M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000, 60:6950-6957.
92. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60:1197-1201.
93. Yarmolenko P.S., Zhao Y., Landon C., Spasojevic I., Yuan F., Needham D., Viglianti B.L., Dewhirst M.W. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int. J. Hyperthermia 2010, 26:485-498.
94. Needham D., Park J.-Y., Wright A.M., Tong J. Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin. Faraday Discuss. 2013, 161:515-534.
95. Anyarambhatla G.R., Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature-sensitive liposome for use with mild hyperthermia. J. Liposome Res. 1999, 9:491-506.
96. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 2001, 53:285-305.
97. Ickenstein L.M., Edwards K., Karlsson G., Mayer L.D. Formation of bilayer discs in lysolipid-containing thermosensitive liposomes during phase transition: a new drug release mechanism. J. Liposome Res. 2003, 13:39-40.
98. Sandstrom M.C., Ickenstein L.M., Mayer L.D., Edwards K. Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J. Control. Release 2005, 107:131-142.
99. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
100. Mills J.K., Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim. Biophys. Acta Biomembr. 2005, 1716:77-96.
101. Lindner L.H., Eichhorn M.E., Eibl H., Teichert N., Schmitt-Sody M., Issels R.D., Dellian M. Novel temperature-sensitive liposomes with prolonged circulation time. Clin. Cancer Res. 2004, 10:2168-2178.
102. Hossann M., Wiggenhorn M., Schwerdt A., Wachholz K., Teichert N., Eibl H., Issels R.D., Lindner L.H. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim. Biophys. Acta 2007, 1768:2491-2499.
103. Tagami T., Ernsting M.J., Li S.D. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J. Control. Release 2011, 154:290-297.
104. Park S.M., Kim M.S., Park S.J., Park E.S., Choi K.S., Kim Y.S., Kim H.R. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU). J. Control. Release 2013, 170:373-379.
105. Dreher M.R., Raucher D., Balu N., Colvin O.M., Ludeman S.M., Chilkoti A. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J. Control. Release 2003, 91:31-43.
106. Abraham S.A., Edwards K., Karlsson G., MacIntosh S., Mayer L.D., McKenzie C., Bally M.B. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim. Biophys. Acta 2002, 1565:41-54.
107. Viglianti B.L., Abraham S.A., Michelich C.R., Yarmolenko P.S., MacFall J.R., Bally M.B., Dewhirst M.W. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn. Reson. Med. 2004, 51:1153-1162.
108. Kheirolomoom A., Lai C.Y., Tam S.M., Mahakian L.M., Ingham E.S., Watson K.D., Ferrara K.W. Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia. J. Control. Release 2013, 172:266-273.
109. Caride V.J., Sostman H.D., Winchell R.J., Gore J.C. Relaxation enhancement using liposomes carrying paramagnetic species. Magn. Reson. Imaging 1984, 2:107-112.
110. Magin R.L., Wright S.M., Niesman M.R., Chan H.C., Swartz H.M. Liposome delivery of NMR contrast agents for improved tissue imaging. Magn. Reson. Med. 1986, 3:440-447.
111. Devoisselle J.M., Vion-Dury J., Galons J.P., Confort-Gouny S., Coustaut D., Canioni P., Cozzone P.J. Entrapment of gadolinium-DTPA in liposomes. Characterization of vesicles by P-31 NMR spectroscopy. Invest. Radiol. 1988, 23:719-724.
112. Unger E., Needleman P., Cullis P., Tilcock C. Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress. Invest. Radiol. 1988, 23:928-932.
113. Langereis S., Geelen T., Grull H., Strijkers G.J., Nicolay K. Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. NMR Biomed. 2013, 26:728-744.
114. Terreno E., Castelli D.D., Viale A., Aime S. Challenges for molecular magnetic resonance imaging. Chem. Rev. 2010, 110:3019-3042.
115. Castelli D.D., Terreno E., Longo D., Aime S. Nanoparticle-based chemical exchange saturation transfer (CEST) agents. NMR Biomed. 2013, 26:839-849.
116. Bacic G., Niesman M.R., Bennett H.F., Magin R.L., Swartz H.M. Modulation of water proton relaxation rates by liposomes containing paramagnetic materials. Magn. Reson. Med. 1988, 6:445-458.
117. Tilcock C., Unger E., Cullis P., MacDougall P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology 1989, 171:77-80.
118. Koenig S.H., Ahkong Q.F., Brown R.D., Lafleur M., Spiller M., Unger E., Tilcock C. Permeability of liposomal membranes to water: results from the magnetic field dependence of T1 of solvent protons in suspensions of vesicles with entrapped paramagnetic ions. Magn. Reson. Med. 1992, 23:275-286.
119. Fossheim S.L., Il'yasov K.A., Hennig J., Bjornerud A. Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad. Radiol. 2000, 7:1107-1115.
120. de Zwart J.A., Salomir R., Vimeux F., Klaveness J., Moonen C.T.W. On the feasibility of local drug delivery using thermo-sensitive liposomes and MR-guided focused ultrasound. Proc. Int. Soc. Magn. Reson. Med. 2000, 8.
121. McDannold N., Fossheim S.L., Rasmussen H., Martin H., Vykhodtseva N., Hynynen K. Heat-activated liposomal MR contrast agent: initial in vivo results in rabbit liver and kidney. Radiology 2004, 230:743-752.
122. 1H MR T1-shortening gadodiamide. Contrast Media Mol. Imaging 2008, 3:19-26.
123. Peller M., Schwerdt A., Hossann M., Reinl H.M., Wang T., Sourbron S., Ogris M., Lindner L.H. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Invest. Radiol. 2008, 43:877-892.
124. Hossann M., Wang T., Syunyaeva Z., Wiggenhorn M., Zengerle A., Issels R.D., Reiser M., Lindner L.H., Peller M. Non-ionic Gd-based MRI contrast agents are optimal for encapsulation into phosphatidyldiglycerol-based thermosensitive liposomes. J. Control. Release 2013, 166:22-29.
125. Viglianti B.L., Ponce A.M., Michelich C.R., Yu D., Abraham S.A., Sanders L., Yarmolenko P.S., Schroeder T., MacFall J.R., Barboriak D.P., Colvin O.M., Bally M.B., Dewhirst M.W. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn. Reson. Med. 2006, 56:1011-1018.
126. de Smet M., Langereis S., van den Bosch S., Grull H. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J. Control. Release 2010, 143:120-127.
127. Negussie A.H., Yarmolenko P.S., Partanen A., Ranjan A., Jacobs G., Woods D., Bryant H., Thomasson D., Dewhirst M.W., Wood B.J., Dreher M.R. Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int. J. Hyperthermia 2011, 27:140-155.
128. Tagami T., Foltz W.D., Ernsting M.J., Lee C.M., Tannock I.F., May J.P., Li S.D. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials 2011, 32:6570-6578.
129. 19F contrast agent for MR image-guided drug delivery. J. Am. Chem. Soc. 2009, 131:1380-1381.
130. Lorenzato C., Cernicanu A., Meyre M.-E., Germain M., Pottier A., Levy L., de Senneville B.D., Bos C., Moonen C. MRI contrast variation of thermosensitive magnetoliposomes triggered by focused ultrasound: a tool for image-guided local drug delivery. Contrast Media Mol. Imaging 2012, 8:185-192.
131. Frich L., Bjornerud A., Fossheim S., Tillung T., Gladhaug I. Experimental application of thermosensitive paramagnetic liposomes for monitoring magnetic resonance imaging guided thermal ablation. Magn. Reson. Med. 2004, 52:1302-1309.
132. Ponce A.M., Viglianti B.L., Yu D., Yarmolenko P.S., Michelich C.R., Woo J., Bally M.B., Dewhirst M.W. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J. Natl. Cancer Inst. 2007, 99:53-63.
133. Lorenzato C., Cernicanu A., Meyre M.E., Germain M., Pottier A., Levy L., de Senneville B.D., Bos C., Moonen C., Smirnov P. MRI contrast variation of thermosensitive magnetoliposomes triggered by focused ultrasound: a tool for image-guided local drug delivery. Contrast Media Mol. Imaging 2013, 8:185-192.
134. Grull H., Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J. Control. Release 2012, 161:317-327.
135. May J.P., Li S.D. Hyperthermia-induced drug targeting. Expert Opin. Drug Deliv. 2013, 10:511-527.
136. Hijnen N.M., Elevelt A., Pikkemaat J., Bos C., Bartels L.W., G.H. The magnetic susceptibility effect of gadolinium-based contrast agents on PRFS-based MR thermometry during thermal interventions. J. Ther. Ultrasound 2013, 1:8.
137. de Smet M., Hijnen N.M., Langereis S., Elevelt A., Heijman E., Dubois L., Lambin P., Grull H. Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin. Invest. Radiol. 2013, 48:395-405.
138. Rohrer M., Bauer H., Mintorovitch J., Requardt M., Weinmann H.J. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest. Radiol. 2005, 40:715-724.
139. Li L., ten Hagen T.L., Bolkestein M., Gasselhuber A., Yatvin J., van Rhoon G.C., Eggermont A.M., Haemmerich D., Koning G.A. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J. Control. Release 2013, 167:130-137.
140. de Smet M., Langereis S., van den Bosch S., Bitter K., Hijnen N.M., Heijman E., Grull H. SPECT/CT imaging of temperature-sensitive liposomes for MR-image guided drug delivery with high intensity focused ultrasound. J. Control. Release 2013, 169:82-90.
141. Manzoor A.A., Lindner L.H., Landon C.D., Park J.Y., Simnick A.J., Dreher M.R., Das S., Hanna G., Park W., Chilkoti A., Koning G.A., Ten Hagen T.L., Needham D., Dewhirst M.W. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012, 72:5566-5575.
142. Staruch R.M., Ganguly M., Tannock I.F., Hynynen K., Chopra R. Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. Int. J. Hyperthermia 2012, 28:776-787.
143. Koning G.A., Eggermont A.M., Lindner L.H., ten Hagen T.L. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm. Res. 2010, 27:1750-1754.
144. Gasselhuber A., Dreher M.R., Negussie A., Wood B.J., Rattay F., Haemmerich D. Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. Int. J. Hyperthermia 2010, 26:499-513.
145. Weinberg B.D., Patel R.B., Exner A.A., Saidel G.M., Gao J. Modeling doxorubicin transport to improve intratumoral drug delivery to RF ablated tumors. J. Control. Release 2007, 124:11-19.
146. Gasselhuber A., Dreher M.R., Rattay F., Wood B.J., Haemmerich D. Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. PLoS One 2012, 7:e47453.
147. Staruch R., Chopra R., Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int. J. Hyperthermia 2011, 27:156-171.
148. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994, 54:3352-3356.
149. Seynhaeve A.L., Hoving S., Schipper D., Vermeulen C.E., de Wiel-Ambagtsheer G., van Tiel S.T., Eggermont A.M., Ten Hagen T.L. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 2007, 67:9455-9462.
150. Gasselhuber A., Dreher M.R., Partanen A., Yarmolenko P.S., Woods D., Wood B.J., Haemmerich D. Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivovalidation. Int. J. Hyperthermia 2012, 28:337-348.
151. ClinicalTrials.gov Phase 3 study of ThermoDox with radiofrequency ablation (RFA) in treatment of hepatocellular carcinoma (HCC) 2011, M.N. Borys (Ed.).
152. Goldberg S.N., Girnan G.D., Lukyanov A.N., Ahmed M., Monsky W.L., Gazelle G.S., Huertas J.C., Stuart K.E., Jacobs T., Torchillin V.P., Halpern E.F., Kruskal J.B. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002, 222:797-804.
153. Head H.W., Dodd G.D., Bao A., Soundararajan A., Garcia-Rojas X., Prihoda T.J., McManus L.M., Goins B.A., Santoyo C.A., Phillips W.T. Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology 2010, 255:405-414.
154. Lencioni R. New IO Approaches for HCC: an update on clinical trials http://www.Celsion.com.
155. Dromi S., Frenkel V., Luk A., Traughber B., Angstadt M., Bur M., Poff J., Xie J., Libutti S.K., Li K.C.P., Wood B.J. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin. Cancer Res. 2007, 13:2722-2727.
156. Patel P.R., Luk A., Durrani A., Dromi S., Cuesta J., Angstadt M., Dreher M.R., Wood B.J., Frenkel V. In vitro and in vivo evaluations of increased effective beam width for heat deposition using a split focus high intensity ultrasound (HIFU) transducer. Int. J. Hyperthermia 2008, 24:537-549.
157. Staruch R., Chopra R., Hynynen K. Hyperthermia in bone generated with MR imaging-controlled focused ultrasound: control strategies and drug delivery. Radiology 2012, 263:117-127.